These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Clinical pharmacokinetics of antiarrhythmic drugs. Harrison DC; Meffin PJ; Winkle RA Prog Cardiovasc Dis; 1977; 20(3):217-42. PubMed ID: 335439 [No Abstract] [Full Text] [Related]
5. [Pharmacokinetics of the principal anti-arrhythmia agents]. Derrida JP; Chiche P Coeur Med Interne; 1978; 17(1):79-88. PubMed ID: 25160 [No Abstract] [Full Text] [Related]
6. Cardiac drug overdose. Drake CE Am Fam Physician; 1982 Jan; 25(1):181-7. PubMed ID: 7055025 [TBL] [Abstract][Full Text] [Related]
7. Series on pharmacology in practice. 2. Antiarrhythmic drug therapy. Federman J; Vlietstra RE Mayo Clin Proc; 1979 Aug; 54(8):531-42. PubMed ID: 459565 [TBL] [Abstract][Full Text] [Related]
8. [Pharmacokinetics of the principal anti-arrhythmic drugs. Measurement of their blood levels]. Cheymol G; Bernheim C; Jaillon P Therapie; 1976; 31(2):149-65. PubMed ID: 951673 [No Abstract] [Full Text] [Related]
10. [Determination of plasma concentrations of anti-arrhythmia agents]. Flouvat B Arch Mal Coeur Vaiss; 1981 Dec; 74 Spec No():47-55. PubMed ID: 6803701 [TBL] [Abstract][Full Text] [Related]
11. Metabolites of antiarrhythmic drugs: are they clinically important? Kates RE Ration Drug Ther; 1986 May; 20(5):1-5. PubMed ID: 3097754 [No Abstract] [Full Text] [Related]
12. [Clinical pharmacology of anti-arrhythmia agents. I. Quinidine, procainamide and disopyramide]. Witkowska M Kardiol Pol; 1981; 24(7):505-17. PubMed ID: 7024612 [No Abstract] [Full Text] [Related]
13. Effects of congestive heart failure on the pharmacokinetics and pharmacodynamics of antiarrhythmic agents. Woosley RL; Echt DS; Roden DM Am J Cardiol; 1986 Jan; 57(3):25B-33B. PubMed ID: 3080860 [TBL] [Abstract][Full Text] [Related]
14. Human organic cation transporter 3 mediates the transport of antiarrhythmic drugs. Hasannejad H; Takeda M; Narikawa S; Huang XL; Enomoto A; Taki K; Niwa T; Jung SH; Onozato ML; Tojo A; Endou H Eur J Pharmacol; 2004 Sep; 499(1-2):45-51. PubMed ID: 15363950 [TBL] [Abstract][Full Text] [Related]
15. Interaction of antacids with antiarrhythmics. V. Effect of aluminium hydroxide and magnesium oxide on the bioavailability of quinidine, procainamide and propranolol in dogs. Remon JP; Belpaire F; Van Severen R; Braeckman P Arzneimittelforschung; 1983; 33(1):117-20. PubMed ID: 6681962 [TBL] [Abstract][Full Text] [Related]
16. [Pharmacokinetics and plasma concentrations of anti-arrhythmic drugs]. Jaillon P Ann Cardiol Angeiol (Paris); 1984 Dec; 33(8):525-30. PubMed ID: 6529130 [TBL] [Abstract][Full Text] [Related]
17. Binding of antiarrhythmic drugs to human placenta in vitro. Bailey DN Ann Clin Lab Sci; 1999; 29(3):209-12. PubMed ID: 10440585 [TBL] [Abstract][Full Text] [Related]
18. Individualization of dosage of antiarrhythmic drugs. Kessler KM Med Clin North Am; 1974 Sep; 58(5):1019-26. PubMed ID: 4609363 [No Abstract] [Full Text] [Related]
19. Clinical application of pharmacokinetics for antiarrhythmic drugs. Harrison DC Arch Mal Coeur Vaiss; 1981 Dec; 74 Spec No():65-72. PubMed ID: 6803703 [TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of propranolol, quinidine, procainamide and lidocaine in chronic renal disease. Lowenthal DT Am J Med; 1977 Apr; 62(4):532-8. PubMed ID: 851126 [No Abstract] [Full Text] [Related] [Next] [New Search]